• Login
    View Item 
    •   Home
    • Yale
    • Yale Journal of Health Policy, Law, and Ethics
    • View Item
    •   Home
    • Yale
    • Yale Journal of Health Policy, Law, and Ethics
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of openYLSCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Regulatory Paternalism in the Market for Drugs: Lessons from Vioxx and Celebrex

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    31_5YaleJHealthPolyL_Ethics741 ...
    Size:
    1.881Mb
    Format:
    PDF
    Download
    Author
    Epstein, Richard
    
    Metadata
    Show full item record
    URI
    http://hdl.handle.net/20.500.13051/6063
    Abstract
    The trials and tribulations of the pharmaceutical industry made front-page news in the Fall of 2004. On September 30, 2004, Merck & Co. announced that it would voluntarily pull its Cox-2 inhibitor, Vioxx, from the market. To say the least, the decision to take the drug off the market caused no little stir. Vioxx, which had entered the market with great fanfare in 1999, had become an instant blockbuster drug with over one hundred million prescriptions, twenty million users, and about $2.5 billion in annual sales. The success of the drug paralleled that of two Pfizer Cox-2 inhibitors, Celebrex and Bextra. The success of all three drugs is (or at least, was) attributable to their apparent ability to satisfy the best of both possible worlds by relieving pain without provoking the risk of stomach or intestinal bleeding inherent to ibuprofen and similar drugs. The number "2" appended to the term Cox, with respect to drugs such as Vioxx, signified a welcome measure of specificity. Drugs in this family could work effectively where needed without causing disruption where they were not wanted. Indeed, Merck had such confidence in the ability of Vioxx to specifically target its effects that the company was seeking to expand the portfolio of permissible uses by raising the dosage to determine the effectiveness of Vioxx in treating polyps-intestinal growths that could become cancerous. However, during these trials, Merck discovered in its own clinical data an apparent increase in the number of negative cardiovascular occurrences, which, if extrapolated, "may" suggest that as many as 27,000 persons had died from the use of the product.
    Collections
    Yale Journal of Health Policy, Law, and Ethics

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.